Handelsavisen
prelaunch
Companies Healthcare XLY.TO
XL
XLY.TO Toronto Stock Exchange Pharmaceuticals

Auxly Cannabis Group Inc

C$0,16
Open in Charts → Attach watcher ⌖
CAD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-38,9 %
ROE
-25,0 %
Net margin
-103,1 %
Debt / equity
0,79
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Auxly Cannabis Group Inc is a Canadian company that operates in the pharmaceuticals and medical research sector, focusing on cannabis-based products and therapies.

Business. Auxly Cannabis Group Inc (XLY.TO) is a healthcare company operating within the pharmaceuticals and medical research industry. The firm is headquartered in Canada and is primarily listed on the Toronto Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target0,25

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
0,25
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
AMERIPRISE FINANCIAL INC
largest disclosed fund holder
Profitability
-25,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning XLY.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to XLY.TO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Auxly Cannabis Group Inc (XLY.TO) is a healthcare company operating within the pharmaceuticals and medical research industry. The firm is headquartered in Canada and is primarily listed on the Toronto Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Auxly Cannabis Group Inc has a liquidity position that is below the industry median, with a current ratio of 0.71, indicating that the company's current assets are insufficient to cover its current liabilities. The company's cash and equivalents amount to 13,079,000 CAD, while its long-term debt stands at 81,727,000 CAD, resulting in a debt-to-equity ratio of 0.79. This suggests that the company is moderately leveraged but not in a high-risk debt position.

    The company's profitability is weak, with a net loss of 26,012,000 CAD and an operating loss of 9,829,000 CAD. Its return on equity is -24.99%, and its return on assets is -10.00%, both of which are significantly below the industry median for pharmaceutical companies. These metrics indicate that the company is not generating returns for its shareholders or effectively utilizing its assets.

    Auxly Cannabis Group Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements. The company does not provide detailed geographic revenue breakdowns, but its operations are primarily based in Canada. This concentration increases the company's exposure to local market conditions and regulatory changes.

    The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. The lack of positive revenue growth, combined with ongoing losses, suggests that the company is struggling to achieve profitability. Analysts have assigned a mean price target of 0.25 CAD, with a mean recommendation of 2.00, indicating a neutral stance.

    The company faces several risk factors, including liquidity constraints and the potential for dilution. The risk assessment indicates a medium liquidity risk, with the company's net cash position being negative after accounting for total debt. The dilution risk is currently low, but the company's ongoing losses and capital expenditures may necessitate future equity raises, which could dilute existing shareholders.

    Recent events, including the company's financial performance and analyst estimates, suggest that the company is under pressure to improve its financial position. The company has not disclosed any major new product launches or strategic initiatives that could drive future growth. The lack of positive developments may continue to impact investor sentiment and the company's stock price.

    Key takeaways
    • Auxly Cannabis Group Inc is operating at a net loss with a return on equity of -24.99% and a return on assets of -10.00%.
    • The company's liquidity position is weak, with a current ratio of 0.71 and a debt-to-equity ratio of 0.79.
    • Revenue is concentrated in a single business segment, increasing exposure to local market conditions.
    • Analysts have assigned a neutral stance with a mean price target of 0.25 CAD.
    • The company faces liquidity and dilution risks, with ongoing losses and capital expenditures.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Auxly generated CAD 122.3 million in revenue during FY-1, representing a 21% year-over-year increase from the prior period.

    The company achieved positive operating income of CAD 1.1 million in FY-1, marking a significant turnaround from previous losses.

    Analyst consensus suggests a 56.2% upside potential, with a mean price target of CAD 0.25 versus the current market price.

    Long-term debt decreased significantly to CAD 68.5 million in FY-1, down from CAD 159.0 million in the prior period.

    Gross profit expanded to CAD 53.5 million in FY-1, indicating improved core profitability before operating expenses.

    BEAR CASE · 2

    The company faces high credit risk and medium liquidity risk, posing significant financial stability concerns for investors.

    Free cash flow remained negative at CAD 8.8 million in FY-1, highlighting ongoing cash burn despite revenue growth.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-26
    Q4 2025 · Quarter highlights

    Revenue C$40.1M, +15,8% YoY; Operating income −80,9% YoY.

    RevenueC$40.1M+15,8 % YoY
    Operating incomeC$994.0k−80,9 % YoY
    Net incomeC$943.0k−78,7 % YoY
    Free cash flowC$3.4M−43,0 % YoY
    EPS
    Operating cash flowC$26.2M+56,1 % YoY
    Financials
    Income statement
    RevenueC$40.1M
    Gross profitC$22.3M
    Operating incomeC$994.0k
    Net incomeC$943.0k
    Margins
    Gross margin55.5%
    Operating margin2.5%
    Net margin2.4%
    FCF margin8.5%
    Balance sheet
    Total assetsC$271.6M
    Total liabilitiesC$94.1M
    Total equityC$177.6M
    Cash & equivalentsC$32.3M
    Long-term debtC$57.6M
    Cash flow
    Operating cash flowC$26.2M
    CapEx-C$2.5M
    Free cash flowC$3.4M
    SBC
    P&L flow · revenue → net income
    Revenue C$40.1MOperating costs C$39.1MTax C$51.0kNet income C$943.0k
    Highlights
    • Revenue C$40.1M, +15,8% YoY
    • Operating income −80,9% YoY
    • Net income −78,7% YoY
    • Free cash flow −43,0% YoY
    • Net margin 2.4%

    Valuation FY

    Market price
    C$0,16
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    C$104.1M
    Net cash
    -C$68.6M
    Current ratio
    0.7
    Debt / equity
    0.8
    ROA
    -10.0%
    ROE
    -25.0%
    Cash conversion
    9.0%
    CapEx / revenue
    -1.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,01
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-13 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,01
    Revenueno estimateno estimate162,6M CAD
    Operating incomeno estimateno estimateno estimate
    Full-year consensus mean (period as reported by source) · consensus in CAD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price targetC$0,25 · Median C$0,25
    Low C$0,25High C$0,25
    EPS surprise
    +200,0 %
    reported vs consensus · beat
    Revenue surprise
    −6,8 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowC$0,25
    MeanC$0,25
    MedianC$0,25
    HighC$0,25
    SpotC$0,16
    +56.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-38,9 %Bottom quartile
    Net Margin-103,0 %Bottom quartile
    ROE-25,0 %Bottom quartile
    Capex / Rev-1,2 %Above P75
    D/E0,79Bottom quartile
    Cash Conv0,09Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Auxly Cannabis Group Inc Market data — financials · 2026-05-30
    • Auxly Cannabis Group Inc Market data — analyst estimates · 2026-05-30

    Ownership & reference

    Top holders

    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,07 %$308M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$12M

    Insider activity

    — missing data

    Short positioning

    9.9Mshares short-15.6% vs prior
    1.1days to cover
    59.7%short of daily vol
    73.9Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    XLY.TOCanonical
    Toronto Stock Exchange · CAD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-03-26 07:47 UTCEARNINGSQuarterly results — Q4 2025 Revenue CAD 40.1M · Net CAD 0.9M
    2026-03-26 07:47 UTCEARNINGSAnnual results — FY 2026 Revenue CAD 151.5M · Net CAD 41.9M
    2023-03-31 07:30 UTCEARNINGSAnnual results — FY 2023 Revenue CAD 94.5M · Net CAD -130.3M
    2022-03-31 07:09 UTCEARNINGSAnnual results — FY 2022 Revenue CAD 83.8M · Net CAD -33.7M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage